Financial Statements - Solvay
Financial Statements - Solvay
Financial Statements - Solvay
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
86<br />
<strong>Solvay</strong> Global Annual Report 2008<br />
(23) Goodwill<br />
EUR Million Total<br />
Gross carrying amount<br />
At 31 December 2006 1 214<br />
Arising on acquisitions 32<br />
Change in consolidation scope 0<br />
Impairments -26<br />
Currency translation differences -10<br />
Other 0<br />
At 31 December 2007 1 210<br />
Arising on acquisitions 483<br />
Change in consolidation scope -10<br />
Impairments 0<br />
Currency translation differences -10<br />
Transfer to assets held for sale -4<br />
Other -3<br />
At 31 December 2008 1 667<br />
In 2008, the increase in goodwill comes from:<br />
– the recognition of an earn-out and milestones payable to the former Fournier shareholders (EUR 200 million),<br />
– the acquisition of Innogenetics (EUR 212 million),<br />
– the acquisition of Alexandria Sodium Carbonate Co (EUR 66 million).<br />
The goodwill impairment tests did not lead to any impairment losses being recognized in 2008. For these tests, the Group<br />
prepares cash-fl ow forecasts based on the most recent fi nancial projections approved by executive management for<br />
the next fi ve years. For the following years, the extrapolation of the cash fl ows is based on a growth rate which does not<br />
exceed the average long-term growth rate of the markets in question.<br />
The forecasted cash fl ows for each of the cash-generating units concerned have been discounted to net present value<br />
at specifi c rates, based on external references and measuring the risks inherent to the specifi c sector and geographic<br />
location of the cash-generating units. These discount rates range between 8.3 % and 9.3 %, to which country risk<br />
premiums can in some cases be added (up to 6 %).<br />
The essential part of the goodwill comes from the Fournier acquisition (EUR 1 221 million) and from the Innogenetics<br />
acquisition (EUR 212 million). To the extent that this goodwill represents in each country synergies which will benefi t<br />
all Pharmaceuticals Sector products, goodwill cannot be allocated by product, but only by region. As a result, the cashgenerating<br />
units used for the annual impairment tests on this particular goodwill item are based on the regions.